OncoGenex

OncoGenex is a leader in the development of novel therapeutics that target important mechanisms of treatment resistance in cancer. We are committed to the development and commercialization of first-in-class, innovative therapies that have the potential to redefine treatment outcomes for patients with a variety of cancers.
Company Growth (employees)
Type
Public
HQ
Bothell, US
Size (employees)
17 (est)
OncoGenex is headquartered in Bothell, US

Key People at OncoGenex

Scott Cormack

Scott Cormack

President & Chief Executive Officer
David V. Smith

David V. Smith

Director

OncoGenex Office Locations

OncoGenex has offices in Bothell and Vancouver
Bothell, US (HQ)
201 19820 North Creek Pkwy
Vancouver, CA
400 1001 W Broadway

OncoGenex Data and Metrics

OncoGenex Financial Metrics

USD

Net income (Q1, 2017)

(3.3 m)

Market capitalization (17-Aug-2017)

8.2 m

Cash (31-Mar-2017)

15.7 m
OncoGenex's current market capitalization is $8.2 m.
USDFY, 2013FY, 2016

R&D expense

14.8 m

General and administrative expense

8.9 m

Operating expense total

26.3 m

EBIT

(28.4 m)

Interest income

203 k

Net Income

(31.8 m)(20.1 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

9.9 m9.6 m3.7 m6.5 m8.3 m4.6 m4.7 m3.8 m912 k

General and administrative expense

2.7 m2.5 m2.7 m3.1 m3.1 m2.3 m2.5 m1.9 m2.5 m

Operating expense total

12.6 m12 m6.4 m9.6 m11.4 m6.9 m7.1 m5.6 m3.4 m

Interest income

4 k3 k54 k13 k24 k48 k61 k53 k27 k

Net Income

(15.7 m)(20.6 m)(4.5 m)(10.5 m)(15.1 m)(3.7 m)(10.6 m)(14.3 m)(3.3 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

14.6 m27.9 m34.3 m15.2 m

Accounts Receivable

218 k113 k111 k32 k

Current Assets

53.9 m55.8 m57.3 m26.9 m

PP&E

397 k257 k602 k258 k

Total Assets

55.7 m56.3 m58.2 m27.5 m

Accounts Payable

139 k72 k1.3 m2.1 m

Current Liabilities

14.9 m22.2 m20.7 m8.5 m

Total Liabilities

8.5 m

Additional Paid-in Capital

168.2 m191.4 m211.6 m213.2 m

Retained Earnings

(133.7 m)(160 m)(176.8 m)(196.9 m)

Total Equity

37.2 m37.4 m19 m

Financial Leverage

1.5 x1.6 x1.4 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

40.6 m49 m25.3 m48 m42.5 m18.9 m10.6 m11.8 m15.7 m

Accounts Receivable

19 k71 k76 k48 k53 k47 k36 k32 k

Current Assets

47.9 m61.3 m45.5 m62.7 m67.6 m48 m41.4 m34.3 m17.5 m

PP&E

354 k312 k416 k406 k380 k546 k534 k493 k166 k

Total Assets

49.7 m62.7 m46.4 m63.4 m68.2 m48.8 m42.2 m35.1 m17.9 m

Accounts Payable

1.3 m1.6 m988 k302 k1.8 m592 k559 k1 m359 k

Current Liabilities

20.2 m20.9 m16.2 m35 m29.3 m14.5 m13.9 m10.6 m2 m

Additional Paid-in Capital

173.1 m190.5 m191.9 m196.1 m211.2 m212.1 m213 m212.8 m213.5 m

Retained Earnings

(149.3 m)(154.3 m)(164.5 m)(170.5 m)(175.1 m)(180.5 m)(187.4 m)(191.1 m)(200.2 m)

Total Equity

26.5 m38.9 m30 m28.2 m38.8 m34.2 m28.2 m24.4 m15.9 m

Financial Leverage

1.9 x1.6 x1.5 x2.2 x1.8 x1.4 x1.5 x1.4 x1.1 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(31.8 m)(26.2 m)(16.8 m)(20.1 m)

Depreciation and Amortization

227 k223 k244 k188 k

Accounts Receivable

109 k105 k2 k79 k

Accounts Payable

(1.2 m)(67 k)1.3 m778 k

Cash From Operating Activities

(35.9 m)(17.3 m)(9.1 m)(29.7 m)

Purchases of PP&E

(253 k)(82 k)(371 k)(46 k)

Cash From Investing Activities

32.4 m5.4 m(2.1 m)10.6 m

Cash From Financing Activities

10 k25.2 m17.6 m(2 k)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(15.7 m)(20.6 m)(4.5 m)(10.5 m)(15.1 m)(3.7 m)(10.6 m)(14.3 m)(3.3 m)

Depreciation and Amortization

110 k165 k46 k116 k178 k56 k103 k148 k93 k

Accounts Receivable

218 k199 k42 k37 k65 k58 k64 k75 k32 k

Accounts Payable

1.2 m1.4 m916 k230 k1.7 m(751 k)(784 k)(300 k)(1.8 m)

Cash From Operating Activities

(6.4 m)10.2 m1.6 m(15.4 m)(22.7 m)(9 m)

Purchases of PP&E

(67 k)(80 k)(205 k)(265 k)(301 k)(205 k)(35 k)(39 k)(1 k)

Cash From Investing Activities

3.9 m6.7 m(4.6 m)(6.3 m)(8.3 m)194 k9.5 m

Cash From Financing Activities

6.1 m25.2 m(52 k)3.2 m17.6 m(52 k)3.2 m17.6 m(19 k)
Y, 2017

Financial Leverage

1.1 x

OncoGenex Market Value History

Traffic Overview of OncoGenex

OncoGenex Online and Social Media Presence

OncoGenex Company Life and Culture

You may also be interested in